These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 28187335)

  • 1. Insight into illness and its relationship to illness severity, cognition and estimated antipsychotic dopamine receptor occupancy in schizophrenia: An antipsychotic dose reduction study.
    Gerretsen P; Takeuchi H; Ozzoude M; Graff-Guerrero A; Uchida H
    Psychiatry Res; 2017 May; 251():20-25. PubMed ID: 28187335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data.
    Ozzoude M; Nakajima S; Plitman E; Chung JK; Kim J; Iwata Y; Caravaggio F; Takeuchi H; Uchida H; Graff-Guerrero A; Gerretsen P
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 89():207-213. PubMed ID: 30172739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.
    Nørbak-Emig H; Ebdrup BH; Fagerlund B; Svarer C; Rasmussen H; Friberg L; Allerup PN; Rostrup E; Pinborg LH; Glenthøj BY
    Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26819282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study.
    Fervaha G; Caravaggio F; Mamo DC; Mulsant BH; Pollock BG; Nakajima S; Gerretsen P; Rajji TK; Mar W; Iwata Y; Plitman E; Chung JK; Remington G; Graff-Guerrero A
    Psychopharmacology (Berl); 2016 Oct; 233(21-22):3803-3813. PubMed ID: 27557949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.
    Sakurai H; Bies RR; Stroup ST; Keefe RS; Rajji TK; Suzuki T; Mamo DC; Pollock BG; Watanabe K; Mimura M; Uchida H
    Schizophr Bull; 2013 May; 39(3):564-74. PubMed ID: 22290266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
    Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
    Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: an analysis of the CATIE data.
    Takeuchi H; Suzuki T; Bies RR; Remington G; Mamo DC; Pollock BG; Mimura M; Uchida H
    Schizophr Res; 2013 Nov; 150(2-3):373-9. PubMed ID: 24028745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
    Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
    Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
    Ikai S; Remington G; Suzuki T; Takeuchi H; Tsuboi T; Den R; Hirano J; Tsunoda K; Nishimoto M; Watanabe K; Mimura M; Mamo D; Uchida H
    J Clin Psychiatry; 2012 Aug; 73(8):1147-52. PubMed ID: 22967779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropsychological and conditioned blocking performance in patients with schizophrenia: assessment of the contribution of neuroleptic dose, serum levels and dopamine D2-receptor occupancy.
    Oades RD; Rao ML; Bender S; Sartory G; Müller BW
    Behav Pharmacol; 2000 Jun; 11(3-4):317-30. PubMed ID: 11103886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognition and Dopamine D
    Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC; Graff-Guerrero A
    Am J Geriatr Psychiatry; 2017 Jan; 25(1):1-10. PubMed ID: 27745822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
    de Haan L; van Bruggen M; Lavalaye J; Booij J; Dingemans PM; Linszen D
    Am J Psychiatry; 2003 Feb; 160(2):303-9. PubMed ID: 12562577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
    Kapur S; Zipursky RB; Remington G
    Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia.
    Iwata Y; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Plitman E; Chung JK; Mar W; Gerretsen P; Pollock BG; Mulsant BH; Rajji TK; Mamo DC; Graff-Guerrero A
    J Clin Psychiatry; 2016 Dec; 77(12):e1557-e1563. PubMed ID: 28086010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimated dopamine D₂ receptor occupancy and remission in schizophrenia: analysis of the CATIE data.
    Moriguchi S; Bies RR; Remington G; Suzuki T; Mamo DC; Watanabe K; Mimura M; Pollock BG; Uchida H
    J Clin Psychopharmacol; 2013 Oct; 33(5):682-5. PubMed ID: 23899638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications.
    Frankle WG; Gil R; Hackett E; Mawlawi O; Zea-Ponce Y; Zhu Z; Kochan LD; Cangiano C; Slifstein M; Gorman JM; Laruelle M; Abi-Dargham A
    Psychopharmacology (Berl); 2004 Oct; 175(4):473-80. PubMed ID: 15083259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate.
    Nyberg S; Farde L; Halldin C; Dahl ML; Bertilsson L
    Am J Psychiatry; 1995 Feb; 152(2):173-8. PubMed ID: 7840348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia.
    de Haan L; Booij J; Lavalaye J; van Amelsvoort T; Linszen D
    Psychopharmacology (Berl); 2006 Jan; 183(4):500-5. PubMed ID: 16292589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder.
    Potkin SG; Keator DB; Kesler-West ML; Nguyen DD; van Erp TG; Mukherjee J; Shah N; Preda A
    CNS Spectr; 2014 Apr; 19(2):176-81. PubMed ID: 24073841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.